Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 7 of 23
Jul 13, 2026The recent workforce reductions at EMD Serono mark yet another sign of evolving economic pressures in the research-driven pharmaceutical industry. This development, closely tracked by industry watchers, highlights ongoing restructuring efforts and their multifaceted consequences across pharma pipelines, workforce stability, and long-term innovation.
Daniel Cho
Jul 11, 2026A glaucoma drug acquired by Bausch + Lomb failed to meet primary and secondary outcomes in a Phase 2 study, yet the company remains optimistic about its future use in treating geographic atrophy. By pivoting focus to this significant unmet need, Bausch + Lomb aims to innovate in the eye disease space, following setbacks experienced by previous industry leaders.
Emily Carter
Jul 10, 2026A new milestone in oncology drug development has been reached by GSK and Hansoh Pharmaceutical, as their antibody-drug conjugate (ADC) secures a pivotal clinical trial victory. This progress supports their cross-border collaboration and positions the partnership for near-term regulatory success in China, underscoring shifting dynamics in the global cancer therapeutics landscape.
Jonathan Blake
Jul 10, 2026Roche's decision to discontinue its Huntington's disease clinical trials—partnered with Ionis Pharmaceuticals—adds to a string of setbacks for the RNA-focused biotech. The move follows closely after the company's late-stage failure in the ATTR-CM space, challenging Ionis' trajectory in genetic and rare disease innovation.
Sophia Reynolds
Jul 9, 2026In a significant withdrawal within the biopharmaceutical industry, GSK has opted to terminate its alliance with Alector, originally established to co-develop two promising antibodies targeting neurodegenerative diseases. The inability of both assets to demonstrate meaningful clinical benefit underlines the formidable obstacles inherent in neurology drug development and may reshape the landscape for both organizations.
Dr. Priya Nandakumar
Jul 8, 2026A large-scale recall of Corlanor underscores the ongoing quality assurance challenges in global pharmaceutical manufacturing. The event highlights both the vulnerabilities and the critical importance of transparent recall procedures in the international drug supply chain.
Sophia Reynolds
Jul 7, 2026Vertex Pharmaceuticals has announced its $10 billion acquisition of Crinetics Pharmaceuticals, a significant deal in a year shaped by a surge in biotech mergers and acquisitions. This transaction centers around Crinetics’ rare endocrine disorder assets and underscores the industry’s appetite for innovation through strategic consolidation.
Emily Carter
Jul 6, 2026GLP-1 weight-loss drugs are surging in popularity, and the convenience of telehealth has only accelerated demand. But, as a recent study reveals, convenient online prescriptions may be coming at the cost of robust clinical oversight, potentially exposing patients to avoidable risks. This in-depth analysis explores the findings, implications for patients and providers, and the evolving landscape of digital health regulation.
Sophia Reynolds
Jul 2, 2026This new agreement follows recent collaborations between AstraZeneca and CSPC in obesity and chronic disease, underscoring a strategic effort to address global kidney disease challenges through innovative drug development and commercialization in both the China and global markets.
Jonathan Blake
Jul 2, 2026Fresh research published in The Lancet sheds light on how statins and blood pressure medications are transforming cardiovascular risk profiles among adults with obesity, particularly those over 40. Yet while medical advancements appear to narrow some health disparities for older adults, the outlook for younger generations living with obesity remains complex and concerning. This extensive analysis reviews the new findings, discusses implications for clinical practice and public health, and contextualizes them within the broader fight against obesity.
Dr. Priya Nandakumar
Jul 1, 2026As BioCryst Therapeutics ends its in-house discovery programs, the company joins a cohort of firms adapting to shifting industry realities through layoffs and restructuring. This marks a significant strategic pivot aimed at refocusing resources and responding to market and financial pressures.
Michael Torres
Jul 1, 2026Servier’s leadership has outlined a clear strategy focused on bold and innovative science rather than blockbuster drugs. At the BIO International Convention, the company shared its rationale for the high-profile acquisitions of Day One Biopharmaceuticals and Edgewise Therapeutics’ neuromuscular business, suggesting a seismic shift in priorities for big pharma.
Dr. Priya NandakumarMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.